Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant anthropogenic hepatocyte growth factor (HGF) activating factor and application thereof

An activator, human-derived technology, applied in applications, genetic engineering, plant genetic improvement, etc., can solve the problems of lack of treatment methods and high mortality of patients

Inactive Publication Date: 2011-06-15
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The clinical manifestations are severe jaundice, ascites, coagulation disorders, and hepatic encephalopathy. The disease is dangerous, but internal medicine can only adopt liver protection and symptomatic treatment. Due to the lack of effective treatment methods, the mortality rate of patients is as high as 70-90%.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant anthropogenic hepatocyte growth factor (HGF) activating factor and application thereof
  • Recombinant anthropogenic hepatocyte growth factor (HGF) activating factor and application thereof
  • Recombinant anthropogenic hepatocyte growth factor (HGF) activating factor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Preparation of recombinant human HGFA-Fc fusion protein

[0034] Use RT-PCR to catch the HGFA active region DNA fragment (GeneID: 3083, 1104bp ~ 1962bp) from the liver tissue cDNA library with a size of 858bp, and use Overlap overlapping PCR (see Cao Yang et al., "Hebei Medicine", Volume 27, Issue 11, 2005) Fusion with human immunoglobulin Fc (GeneID: 2209) 693bp fragment to obtain 1575bp HGFA-Fc fragment, Xho I / Hind III double digestion and cloning into pcDNA3.1(+) vector. After the enzyme digestion and identification are correct, a large amount of extraction, purification, and concentration determination are used for later use. Specific steps are as follows:

[0035] 1. Construction of recombinant plasmid pcDNA3.1-HGFA-Fc:

[0036] 1. Primer synthesis for amplifying the HGFA-Fc chimeric gene

[0037] The human HGFA gene (ID: 3083) was determined according to the gene library, and primers were designed to amplify the range of 1102bp to 1965bp of the human...

Embodiment 2

[0070] Example 2: Enzyme cleavage activity and anti-apoptosis effect of rhHGFA-Fc recombinant fusion protein

[0071] 1. Detection of pro-HGF enzyme activity activated by HGFA-Fc:

[0072] In the pro-HGF reaction buffer with a final concentration of 50ug / ml, add HGFA-Fc concentration gradients of 0.15ug / ml, 0.3ug / ml, 0.6ug / ml, 0.12ug / ml, 0.24ug / ml, 4.8 ug / ml, Western blot was used to detect the expression of proHGF (92kD) and HGF (62kD) in each reaction system after 1 hour of reaction. The results show that rhHGFA-Fc recombinant protein can digest pro-HGF into α chain and β chain, and the enzymatic activity increases with the increase of rhHGFA-Fc concentration. The results are shown in Figure 4 . After calculation, the IC50 enzyme activity value of the recombinant protein is 20nM.

[0073] In the pro-HGF solution with a concentration of 50ug / ml, HGFA-Fc fusion protein with a final concentration of 2.4ug / ml was added, and HAI-1 with a final concentration of 0.5uM, 2uM and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biological medicines. A hepatocyte growth factor (HGF) activating factor is plasma protein secreted by hepatocyte, and an activated HGFA is 33Kd polypeptide, is just distributed in the damaged tissues and organs, can activate the monomer HGF secreted by a liver nonparenchyma cell into the HGF at the damaged local part and plays roles of cell protection and tissue repair at the local parts of the damaged tissues and organs. The acute and chronic liver function failure has the main pathological characteristics of large-area hepatocyte apoptosis and necrosisand hepatocyte reproducing function inhibition. The clinical manifestation is dangerous, and the mortality of a patient is as high as 70-90 percent because of lacking an effective curing approach. The invention provides a recombinant anthropogenic HGF activating factor which has a nucleotide sequence and a coded amino acid sequence shown as SEQ ID NO:3 and can be used for an application of preparing a medicine for treating acute or subacute severe hepatitis hepatocyte necrosis.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a recombinant human HGF activator (rhHGFA) and the application of rhHGFA in the preparation of medicines for treating acute or subacute severe hepatitis liver cell necrosis. Background technique [0002] Hepatocyte growth factor activator (HGFA) is a plasma protein secreted by liver cells, GeneID: 3083, activated HGFA is a 33Kd polypeptide, which is only distributed in damaged tissues and organs, and can hepatic nonparenchymal cells in damaged parts The secreted monomeric hepatocyte growth factor (pro-HGF) is activated into HGF, which plays a role in cell protection and tissue repair in damaged tissues and organs (see literature Shia S, Stamos J, Kirchhofer D, et al.Conformational ability in serineprotease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol. 2005 Mar 11; 346(5): 1335-49.; Miyazawa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/21
Inventor 薛峰夏强
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com